Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer-Reference-Cited by-同舟云学术

Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer

Published:2017-02-09 Issue:3 Volume:17 Page:209-215
ISSN:1473-7159
Container-title:Expert Review of Molecular Diagnostics
language:en
Short-container-title:Expert Review of Molecular Diagnostics

Author:

Malapelle Umberto¹,Sirera Rafael²³⁴,Jantus-Lewintre Eloísa²³⁴,Reclusa Pablo⁵⁶,Calabuig-Fariñas Silvia³⁴⁷,Blasco Ana³,Pisapia Pasquale¹,Rolfo Christian⁵⁶,Camps Carlos³⁴⁸⁹

Affiliation:

1. Department of Public Health, University of Naples Federico II, Naples, Italy

2. Department of Biotechnology, Universitat Politècnica de València, Valencia, Spain

3. Department of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain

4. Molecular Oncology Laboratory, Fundación Hospital General Universitario de Valencia, Valencia, Spain

5. Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Antwerp, Belgium

6. Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium

7. Department of Pathology, Universitat de València, Valencia, Spain

8. Department of Medicine, Universitat de València, Valencia, Spain

9. CIBERONC, Valencia, Spain

Funder

FEDER

CIBERONC

Publisher

Informa UK Limited

Subject

Genetics,Molecular Biology,Molecular Medicine,Pathology and Forensic Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737159.2017.1288568

Reference43 articles.

1. Epidemiology of Lung Cancer

2. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

3. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

5. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical applications of circulating biomarkers in non-small cell lung cancer;Frontiers in Cell and Developmental Biology;2024-08-21

2. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer;International Journal of Molecular Sciences;2024-07-19

3. Unravelling the diagnostic pathology and molecular biomarkers in lung cancer;Breathe;2024-06

4. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations;Frontiers in Immunology;2024-05-07

5. Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients;Translational Lung Cancer Research;2024-05